Health Care · Pharmaceutical Preparations

TYRA Tyra Biosciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 186312777 filings
Russell 2000

TYRA at a glance

Tyra Biosciences, Inc. (TYRA, SEC CIK 1863127) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Tyra Biosciences, Inc. (TYRA) shares worth $304.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on September 15, 2026 of 9,078,529 shares at $22.03 per share.
  • In the last 90 days, TYRA insiders reported 1 open-market purchase ($20K) and 0 open-market sales ($0) on Form 4, a net purchase of $20K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
1 buy · 0 sells
Net +$20K
13F holders
25 funds
$304.9M · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in the 2025 Annual Report
  • Carried-forward risks include clinical-trial, regulatory approval, commercialization, and financing uncertainties
  • Continued biotechnology competition and dependence on intellectual-property protection
  • Ongoing need for additional capital to support operations and development programs

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, clinical-stage company with no product revenue
  • Net loss $51.1M vs $29.9M YoY, operating margin not applicable with operating expenses $54.9M
  • Dabogratinib IR NMIBC largest R&D program, $7.3M vs $1.8M YoY; TYRA-200 ICC lowest, $(0.1)M vs $0.0M
  • Cash, equivalents and marketable securities $700.5M at September 30, 2026, financing proceeds $376.2M
  • Runway through 2030; expected higher R&D spending, clinical-trial costs and operating losses, with tariffs and geopolitical risks as headwinds

AI summary of the TYRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Tyra Biosciences’ financial results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for reported financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Initial SURF302 results showed 79% ORR and 64% BOR CR at 60 mg QD across 14 patients
  • Single-lesion patients delivered 100% ORR and 75% BOR CR, supporting planned Phase 3 adjuvant development in 2027
Filed Sep 15, 2026Full analysis →

Item 8.01: Other Events

  • $400.0M gross proceeds from 9,079,000 shares and 9,078,529 pre-funded warrants
  • Underwritten offering priced at $22.03 per share, with underwriters purchasing at $20.7082

Item EX-99.1: Item EX-99.1

  • $400.0M gross equity offering priced at $22.03 per share, materially strengthening Tyra’s funding position
  • 9,079,000 shares plus pre-funded warrants for 9,078,529 shares, creating substantial potential dilution
Filed Sep 9, 2026Full analysis →

Item 8.01: Other Events

  • SURF302 supports selective FGFR3 inhibition, with 60 mg QD identified as the potential registrational adjuvant dose
  • 60 mg cohort: 79% ORR and 64% best overall CR among 14 evaluable participants

AI summaries of TYRA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TYRA

Don't miss the next TYRA filing

  • Alerts as it files. A push when TYRA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TYRA, by share count.
  • Ask anything. An AI agent that reads every TYRA filing and answers with sources.

TYRA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
RA CAPITAL MANAGEMENT, L.P.BuySep 15, 2026$22.03
Harris ToddASep 15, 2026$9.13
Fuhrman AlanASep 15, 2026$9.13
Rueb YuliyaASep 15, 2026$9.13
Verjee RehanBuySep 9, 2026$20.58
Rothenberg Stephen MichaelAMay 28, 2026-
MORE ROBERT JAMay 28, 2026-
Gulfo Adele M.AMay 28, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$79.9M-$104.2M-$132.8M
Net Income-$69.1M-$86.5M-$119.9M
Balance Sheet
Total Assets$225.9M$363.6M$282.6M
Equity-$343.2M$259.2M
ROE--25.2%-46.3%
Per Share
EPS$-1.62$-1.51$-2.01
Cash Flow
Operating CF-$50.1M-$69.8M-$95.1M
CapEx$770K$664K$141K

Source: XBRL data in Tyra Biosciences, Inc. (TYRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TYRA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TYRA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$304.9M
Q2 202626$708.4M
Q1 202626$603.8M
Q4 202522$153.9M
Q3 202523$80.9M
Q2 202523$58.1M
Q1 202519$44.4M
Q4 202416$77.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TYRA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
10-QNov 10, 2026Analysis
SC 13GSep 21, 2026-
4Sep 17, 2026--
SC 13GSep 17, 2026-
4Sep 17, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
8-KSep 15, 2026Analysis-
4Sep 11, 2026--
8-KSep 9, 2026Analysis-
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
SC 13GJul 30, 2026-
8-KJun 2, 2026Analysis
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
10-QMay 13, 2026Analysis
8-KMay 13, 2026Analysis
4May 7, 2026-

Related Health Care companies

All Health Care →

TYRA SEC filings: frequently asked questions

Are TYRA insiders buying or selling?

In the last 90 days, Tyra Biosciences, Inc. (TYRA) officers, directors and 10% owners reported 1 open-market purchase worth $20,000 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TYRA stock?

As of September 30, 2026, the largest Tyra Biosciences, Inc. (TYRA) holders among the 13F filers tracked by SignalX were BlackRock ($73.5 million), T. Rowe Price Group ($56.4 million), State Street Corp ($43.7 million), Vanguard Capital Management LLC ($38.7 million), Franklin Resources ($18.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did TYRA report in its latest 8-K?

Tyra Biosciences, Inc. (TYRA) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Tyra Biosciences’ financial results for the quarter ended September 30, 2026.

What are the latest TYRA SEC filings?

Tyra Biosciences, Inc. (TYRA) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 17, 2026.

What is TYRA's SEC CIK number?

Tyra Biosciences, Inc. (TYRA)'s SEC Central Index Key (CIK) is 1863127. EDGAR lists every TYRA filing under that number.

Ask anything about TYRA

The research agent reads TYRA's filings, financials, insider trades and 13F holders, then answers with sources.